➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Baxter
McKesson
Johnson and Johnson
Medtronic

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 10,071,171

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,071,171
Title:Polypeptide complex comprising non-peptidyl polymer having three functional ends
Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.
Inventor(s): Song; Dae Hae (Seoul, KR), Shin; Jae Hee (Suwon-si, KR), Lee; Mi Ji (Incheon, KR), Hong; Sung Hee (Suwon-si, KR), Kwon; Se Chang (Seoul, KR), Lee; Gwan Sun (Seoul, KR)
Assignee: HANMI SCIENCE CO., LTD. (Hwaseong-si, KR)
Application Number:14/873,321
Patent Claims:1. A protein complex, comprising a physiologically active polypeptide, an immunoglobulin Fc domain and a non-peptidyl polymer having three functional ends, wherein two of the three functional ends of the non-peptidyl polymer are covalently linked to two N-terminals of the immunoglobulin Fc domain and the third of the three functional ends is covalently linked to the physiologically active polypeptide, wherein the physiologically active polypeptide is selected from the group consisting of human growth hormone, growth hormone releasing hormone, growth hormone releasing peptide, interferon, interferon receptor, colony-stimulating factor, glucagon-like peptide, exendin-4 peptide, imidazole acetyl exendin-4 peptide (exendin-4 agonist), A-type natriuretic peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide (CNP), D-type natriuretic peptide (DNP), G protein-coupled receptor, interleukin and interleukin receptor, enzyme, interleukin-binding protein, cytokine-binding protein, macrophage activating factor, macrophage peptide, B-cell factor, T-cell factor, Protein A, cell necrosis glycoprotein, immunotoxin, lymphotoxin, tumor necrosis factor, tumor suppressor, transforming growth factor, alpha-1 anti-trypsin, albumin, .alpha.-lactalbumin, apolipoprotein-E, erythropoietin, highly glycosylated erythropoietin, angiopoeitin, hemoglobin, thrombin, thrombin receptor activating peptide, thrombomodulin, blood factor VII, VIIa, VIII, IX and XIII, plasminogen activator, fibrin-binding peptide, urokinase, streptokinase, hirudin, Protein C, C-reactive protein, rennin inhibitor, superoxide dismutase, leptin, platelet-derived growth factor, epithelial growth factor, epidermal growth factor, angiostatin, angiotensin, bone growth factor, bone stimulating protein, calcitonin, insulin, somatostatin, octreotide (somatostatin agonist), atriopeptin, cartilage inducing factor, elcatonin, connective tissue activating factor, follicle stimulating hormone, luteinizing hormone, luteinizing hormone releasing hormone, nerve growth factor, parathyroid hormone, relaxin, secretin, somatomedin, insulin-like growth factor, adrenocortical hormone, glucagon, cholecystokinin, pancreatic polypeptide, gastrin releasing peptide, corticotropin releasing factor, thyroid stimulating hormone, autotaxin, lactoferrin, myostatin, monoclonal antibody, polyclonal antibody, and an Fab' fragment.

2. The protein complex as defined in claim 1, wherein the immunoglobulin Fc domain is aglycosylated.

3. The protein complex as defined in claim 1, wherein the immunoglobulin Fc domain is composed of one to four different domains selected from the group consisting of C.sub.H1, C.sub.H2, C.sub.H3 and C.sub.H4.

4. The protein complex as defined in claim 3, wherein the immunoglobulin Fc domain further comprises a hinge region.

5. The protein complex as defined in claim 1, wherein the immunoglobulin Fc domain is selected from the group consisting of IgG Fc domain, IgA Fc domain, IgD Fc domain, IgE Fc domain, IgM Fc domain, a combination thereof, and a hybrid thereof.

6. The protein complex as defined in claim 5, wherein the immunoglobulin Fc domain is selected from the group consisting of IgG1 Fc domain, IgG2 Fc domain, IgG3 Fc domain, IgG4 Fc domain, a combination thereof, and a hybrid thereof.

7. The protein complex as defined in claim 5, wherein the immunoglobulin Fc domain is in a form of dimers or multimers (combinations of immunoglobulin Fc), each comprising glycosylated immunoglobulins composed of domains of the same origin.

8. The protein complex as defined in claim 6, wherein the immunoglobulin Fc domain is an IgG4 Fc domain.

9. The protein complex as defined in claim 8, wherein the immunoglobulin Fc domain is a human aglycosylated IgG4 Fc domain.

10. The protein complex as defined in claim 1, wherein the non-peptidyl polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, a copolymer of ethylene glycol and propylene glycol, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, dextran, polyvinyl ethyl ether, polylactic acid (PLA), polylactic-glycolic acid (PLGA), lipopolymer, chitin, hyaluronic acid and a combination thereof.

11. The protein complex as defined in claim 10, wherein the non-peptidyl polymer is a polyethylene glycol.

12. The protein complex as defined in claim 1, wherein the non-peptidyl polymer has a terminal functional group selected from the group consisting of propionaldehyde group, butyl aldehyde group, maleimide group and succinimide derivative.

13. The protein complex as defined in claim 1, wherein the three functional ends of the non-peptidyl polymer bind to N-terminal, functional groups of the immunoglobulin Fc domain and the physiologically active polypeptide, said N-terminal, functional groups being selected from the group consisting of lysine, histidine, cysteine residues and a combination thereof.

14. The protein complex as defined in claim 1, wherein the physiologically active polypeptide is selected from the group consisting of hormone, cytokine, interleukin, interleukin-binding protein, enzyme, antibody, growth factor, transcription factor, and blood factor.

15. The protein complex as defined in claim 1, wherein the physiologically active polypeptide is selected from the group consisting of human growth hormone, interferon-alpha, interferon-beta, granulocyte colony stimulating factor, erythropoietin, exendin-4, imidazole acetyl exendin-4 peptide (exendin-4 agonist), calcitonin, octreotide (somatostatin agonist), BNP and Fab' fragment.

16. A method for preparing a protein complex composed of a physiologically active polypeptide, an immunoglobulin Fc domain and a non-peptidyl polymer having three functional ends, with the linkage of both the physiologically active polypeptide and the immunoglobulin Fc domain to the non-peptidyl polymer via respective covalent bonds, comprising: (1) covalently linking two functional ends of the non-peptidyl polymer to opposite N-terminal amino groups of the immunoglobulin Fc domain to form a conjugate; (2) isolating from the reaction mixture of step (1) the conjugate in which the immunoglobulin Fc domain is covalently linked at N-termini thereof with the non-peptidyl polymer; and (3) covalently linking the physiologically active polypeptide to one free functional end of the non-peptidyl polymer of the isolated conjugate, wherein the physiologically active polypeptide is selected from the group consisting of human growth hormone, growth hormone releasing hormone, growth hormone releasing peptide, interferon, interferon receptor, colony-stimulating factor, glucagon-like peptide, exendin-4 peptide, imidazole acetyl exendin-4 peptide (exendin-4 agonist), A-type natriuretic peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide (CNP), D-type natriuretic peptide (DNP), G protein-coupled receptor, interleukin and interleukin receptor, enzyme, interleukin-binding protein, cytokine-binding protein, macrophage activating factor, macrophage peptide, B-cell factor, T-cell factor, Protein A, cell necrosis glycoprotein, immunotoxin, lymphotoxin, tumor necrosis factor, tumor suppressor, transforming growth factor, alpha-1 anti-trypsin, albumin, .alpha.-lactalbumin, apolipoprotein-E, erythropoietin, highly glycosylated erythropoietin, angiopoeitin, hemoglobin, thrombin, thrombin receptor activating peptide, thrombomodulin, blood factor VII, VIIa, VIII, IX and XIII, plasminogen activator, fibrin-binding peptide, urokinase, streptokinase, hirudin, Protein C, C-reactive protein, rennin inhibitor, superoxide dismutase, leptin, platelet-derived growth factor, epithelial growth factor, epidermal growth factor, angiostatin, angiotensin, bone growth factor, bone stimulating protein, calcitonin, insulin, somatostatin, octreotide (somatostatin agonist), atriopeptin, cartilage inducing factor, elcatonin, connective tissue activating factor, follicle stimulating hormone, luteinizing hormone, luteinizing hormone releasing hormone, nerve growth factor, parathyroid hormone, relaxin, secretin, somatomedin, insulin-like growth factor, adrenocortical hormone, glucagon, cholecystokinin, pancreatic polypeptide, gastrin releasing peptide, corticotropin releasing factor, thyroid stimulating hormone, autotaxin, lactoferrin, myostatin, monoclonal antibody, polyclonal antibody, and an Fab' fragment.

17. The method as defined in claim 16, wherein the immunoglobulin Fc domain is reacted at a molar ratio of from 1:2 to 1:5 with the non-peptidyl polymer in step (1).

18. The method as defined in claim 16, wherein the conjugate is reacted at a molar ratio of from 1:0.5 to 1:0.05 with the physiologically active polypeptide in step (3).

19. The method as defined in claim 16, wherein the reactions in both steps (1) and (3) are conducted in the presence of a reducing agent.

20. The method as defined in claim 19, wherein the reducing agent is selected from the group consisting of sodium cyanoborohydride (NaCNBH.sub.3), sodium borohydride, dimethylamine borate and pyridine borate.

21. A composition, comprising the protein complex of claim 1 and optionally a pharmaceutically acceptable vehicle.

22. The protein complex as defined in claim 1, wherein the protein complex is prepared by the method comprising: (1) covalently linking two functional ends of the non-peptidyl polymer to the N-terminal amino groups of the immunoglobulin Fc domain to form a conjugate; (2) isolating from the reaction mixture of step (1) the conjugate in which the dimeric protein is covalently linked at N-termini thereof with the non-peptidyl polymer and (3) covalently linking the physiological active polypeptide to one of free functional end of the non-peptidyl polymer of the isolated conjugate.

Summary for Patent: ⤷  Try it Free

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
South Korea10-2008-0071766Jul 23, 2008

Details for Patent 10,071,171

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 001 1978-01-16 ⤷  Try it Free HANMI SCIENCE CO., LTD. (Hwaseong-si, KR) 2028-07-23 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 002 1978-01-16 ⤷  Try it Free HANMI SCIENCE CO., LTD. (Hwaseong-si, KR) 2028-07-23 DISCN search
Microbix Biosystems KINLYTIC urokinase INJECTABLE;INJECTION 021846 003 1978-01-16 ⤷  Try it Free HANMI SCIENCE CO., LTD. (Hwaseong-si, KR) 2028-07-23 DISCN search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Dow
Merck
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.